Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents

International Journal of Cancer

Volumn 75, Issue 3, 1998, Pages 432-438

  Céraline, Jocelyn ^a   Deplanque, Gaël ^a   Duclos, Brigitte ^a   Limacher, Jean Marc ^a   Hajri, Amor ^a   Noel, Francine ^a   Orvain, Christophe ^a   Frébourg, Thierry ^b   Klein Soyer, Claudine ^c   Bergerat, Jean Pierre ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN P53;

ARTICLE; CANCER GENETICS; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DNA DAMAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; ULTRAVIOLET RADIATION;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELLS, CULTURED; CISPLATIN; DNA; DNA DAMAGE; DRUG SCREENING ASSAYS, ANTITUMOR; FIBROBLASTS; G2 PHASE; GENE EXPRESSION REGULATION; GENES, P53; HUMANS; MITOSIS; MOLECULAR SEQUENCE DATA; MUTATION; OLIGONUCLEOTIDES, ANTISENSE; RADIATION TOLERANCE; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 2642702621     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980130)75:3<432::AID-IJC17>3.0.CO;2-A     Document Type: Article

References (25)

1. 1 cell-cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. nat. Acad. Sci. (Wash.), 92, 8493-8497 (1995).
2. ALDRIDGE, D.R., ARENDS, M.J. and RADFORD, I.R., Increasing the susceptibility of the rat 208F fibroblast cell line to radiation-induced apoptosis does not alter its clonogenic survival dose-response. Brit. J. Cancer. 71, 571-577 (1995).
3. BARTON, C.M. and LEMOINE, N.R., Anti-sense oligonucleotides directed against p53 have anti-proliferative effects unrelated to effects on p53 expression. Brit. J. Cancer. 71, 429-437 (1995).
4. DEMARCQ, C., BUNCH, R.T., CRESWELL, D. and EASTMAN, A., The role of cell-cycle progression in cisplatin-induced apoptosis in Chinese-hamsterovary cells. Cell Growth Differ., 5, 983-993 (1994).
5. DEPLANQUE, G., CÈRALINE, J., HAJRI, A., DUCLOS, B., LOEFFLER, J.P. and BERGERAT, J.P., Lack of correlation between p53-dependent apoptosis and chemosensitivity in a colon-carcinoma cell line. Proc. Amer. Ass. Cancer Res. (88th annual meeting), (Abstract 2849) (1997).
6. DONEHOWER, L.A., HARVEY, M., SLAGLE, B.L., MCARTHUR, M.J., MONTGOMERY, C.A., JR., BUTEL, J.S. and BRADLEY, A., Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356, 215-221 (1992).
7. FAN, S., SMITH, M.L., RIVET, D.J., II, DUBA, D., ZHAN, Q., KHON, K.W., FORNACE, A.J., JR. and O'CONNOR, P.M., Disruption of p53 function sensitizes breast-cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55, 1649-1654 (1995).
8. FLAMAN, J.M. and 14 OTHERS, A simple p53 functional assay for screening cell lines, blood and tumours. Proc. nat. Acad. Sci. (Wash.), 92, 3963-3967 (1995).
9. FRITSCHE, M., HAESSLER, C. and BRANDNER, G., Induction of nuclear accumulation of the tumour-suppressor protein p53 by DNA-damaging agents. Oncogene, 8, 307-318 (1993).
10. 2 exit of the cell cycle: role in DNA-damage-induced apoptosis. Oncogene, 10, 2263-2270 (1995).
11. 2 checkpoint in p53-independent apoptosis induction by X irradiation. Mol. cell Biol., 15, 5849-5857 (1995).
12. HARRIS, C.C., Structure and function of the p53 tumor-suppressor gene: clues for rational cancer-therapeutic strategies. J. nat. Cancer Inst., 88, 1442-1455 (1996).
13. HAWKINS, D.S., DEMERS, G.W. and GALLOWAY, D.A., Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56, 892-898 (1996).
14. HIROTA, T., HORIUCHI, T. and AKAHANE K., p53 anti-sense oligonucleotide inhibits growth of human colon-tumour and normal cell lines. Japan. J. Cancer Res., 87, 735-742 (1996).
15. KASTAN, M.B., ONYEKWERE, O., SIDRANSKY, D., VOGELSTEIN, B. and CRAIG, R.W., Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311 (1991).
16. LEE, J.M. and BERNSTEIN, A., p53 mutations increase resistance to ionizing radiation. Proc. nat. Acad. Sci. (Wash.), 90, 5742-5746 (1993).
17. 2/M delay and cellular radiosensitivity. Int. J. Radiat. Biol., 66, 373-379 (1994).
18. NELSON, W.G. and KASTAN, M.B., DNA strand breaks: the template alterations that trigger p53-dependent DNA-damage-response pathways. Mol. cell. Biol., 14, 1815-1823 (1994).
19. 2 checkpoint in rodent cells. Mol. cell. Biol., 15, 3722-3730 (1995).
20. + cells to caffeine-induced radiosensitization and override of G: delay. Cancer Res., 55, 1643-1648 (1995).
21. RUDOLTZ, M.S., BERNHARD, E.J., KAO, G.D., MUSCHEL, R.J. and MCKENNA, W.G., Apoptosis, cell-cycle kinetics and clonogenic survival in a solid-tumour model system expressing Bcl-2. Proc. Amer. Ass. Cancer Res. (87th annual meeting) (Abstract 4126) (1996).
22. SKILLING, J.S., SOOD, A., NIEMANN, T., LAGER, D.J. and BULLER, R.E., An abundance of p53 null mutations in ovarian carcinoma. Oncogene, 13, 117-123 (1996).
23. 2/M by p53. Oncogene. 10, 109-115 (1995).
24. 2/M arrest and apoptosis. Nature Med., 2, 72-79 (1996).
25. ZHEN, W., LOVISCEK, K., WALTER, S., GENG, L., KHODAREV, N. and VAUGHAN, N., Altered access to the radiation-induced apoptotic pathway in TK6 cells does not affect clonogenic survival after irradiation. Proc. Amer. Ass. Cancer Res. (87th annual meeting) (Abstract 4127) (1996).